Introduction
============

There is evidence that type 2 diabetes is associated with an increased risk of fractures.[@b1-dmso-9-017]--[@b4-dmso-9-017] Antidiabetic medication may modify fracture risk in patients with type 2 diabetes.[@b5-dmso-9-017] Several observational studies have indicated that insulin treatment is related to an increased risk of fractures.[@b6-dmso-9-017]--[@b8-dmso-9-017] The relationship between insulin treatment and fracture risk may be mediated by hypoglycemic events and an increased risk of falls.[@b9-dmso-9-017] However, observational studies of the effects of drugs are prone to bias, which often results in conflicting results.[@b10-dmso-9-017] For example, a case-control study from Denmark found that use of insulin was associated with a reduced risk of any fractures in diabetes patients.[@b11-dmso-9-017] A stratified analysis for different types of insulin therapy (eg, basal-supported oral therapy \[BOT\], conventional insulin therapy \[CT\], or prandial insulin therapy) has not being carried out so far.[@b11-dmso-9-017]

Thus, there is a need for further longitudinal studies on the relationship between insulin treatment and incidence of fractures in type 2 diabetes. For the present study, longitudinal data from general practices throughout Germany were used (German Disease Analyzer database) (IMS Health, Frankfurt, Germany). The aim was to compare the risk of fractures in type 2 diabetes patients on insulin compared to patients on other antidiabetic medication (oral drugs including injectables, such as GLP-1 receptor agonists). In addition, fracture risk of various types of insulin therapy, including BOT, supplementary insulin therapy (SIT), and CT, was compared. Finally, fracture risk in users of different types of basal insulins (insulin detemir, insulin glargine, NPH insulin) was assessed.

Methods
=======

Study population
----------------

The German Disease Analyzer database includes patient data entered by general practitioners throughout Germany.[@b12-dmso-9-017],[@b13-dmso-9-017] Practices anonymously report all diagnoses *International Statistical Classification of Diseases and Related Health Problems*- 10th Revision (ICD-10), prescriptions (Anatomical Therapeutic Chemical Classification System), hospital admissions, and laboratory test results on an ongoing basis. The validity and representativeness of the Disease Analyzer database have been assessed previously.[@b14-dmso-9-017]

The current study sample included 105,960 type 2 diabetes patients from 1,072 practices who received ≥1 insulin prescription per 180 days during the index period used for this study (January 2000 to August 2014). Patients were excluded from the study when they had diagnosed osteoporosis (ICD-10: M81) or a related treatment (Anatomical Therapeutic Chemical: M05B) recorded at baseline. Further exclusion criteria were bone metastases (ICD-10: C795) and diseases which could have altered bone mineral density (ICD-10: M83--85). Finally, patients with cerebrovascular diseases, including stroke (ICD-10: I60--69), dementia (ICD-10: F01, F03, G30), visual disturbances (ICD-10: H53--54), Morbus Paget (ICD-10: M88), and with glucocorticoid or thiazolidinedione prescriptions were excluded. Patients were also excluded from analyses when a first diagnosis of any fracture was prior to the first insulin prescription.

The primary outcome was fracture incidence (ICD-10: M80, S02, S12, S22, S32, S42, S52, S62, S72, S82, S92, T02, T08, T10, T12) recorded in the database between the index date of first recorded insulin prescription and end of follow-up.

Demographic data included age, sex, health insurance (private/statutory health insurance), diabetes duration, and diabetologist care. Obesity diagnosis, lipid disorders, hypertension, macrovascular complications (coronary heart disease, myocardial infarction, peripheral vascular disease), and prevalence of microvascular complications (retinopathy, neuropathy, nephropathy) were assessed as potential confounders. Obesity diagnosis most likely reflects severe or morbid obesity. Baseline data on body mass index (BMI) and HbA~lc~ were only available for a subgroup (BMI: n=26,490; 25.0%; HbA~lc~: n=70, 920..; 66.9%). Furthermore, a revised version of the Charlson comorbidity score was used as a generic marker of comorbidity.[@b15-dmso-9-017] Covariates were assessed before the start of antidiabetic therapy (mean duration: 2.8 years).

Statistical methods
-------------------

Descriptive statistics were given and differences in characteristics of patients (oral antidiabetic drug \[OAD\] vs insulin; different insulin regimens) were assessed using Student's *t*-tests, Wilcoxon rank sum tests, chi-square, or Kruskal--Wallis tests. Logistic regression models (dependent variable: incident fracture) were used to adjust for age, sex, diabetes duration, diabetologist care, and comorbidity. A final multivariate logistic regression model was fitted using stepwise regression. The level of statistical significance was 5%. The analyses were carried out using SAS version 9.3. Since analysis of anonymous data was performed, this study was exempted from institutional ethical review board oversight. The analysis was carried out following established national[@b16-dmso-9-017] and international good practice recommendations for secondary data analysis.[@b17-dmso-9-017]

Results
=======

Fracture risk in newly prescribed insulin therapy versus OADs
-------------------------------------------------------------

After applying the above-mentioned exclusion criteria, 24,250 type 2 diabetes patients with incident insulin therapy were included in the analyses. The mean follow-up after first insulin prescription until incidence of fracture or end of observation was 2.0 years. Overall, 842 (3.5%) patients experienced ≥1 fracture documented in the practice records after onset of insulin therapy ([Table 1](#t1-dmso-9-017){ref-type="table"}). As a control group, 81,710 type 2 diabetes patients without insulin prescriptions were included who received any OAD during the observation period (mean follow-up: 2.5 years). There were 3,508 (4.3%) patients with ≥1 fracture among OAD users.

Patients with first insulin prescription were older, had more often microvascular complications of diabetes, and were more frequently in diabetologist care than OAD users ([Table 1](#t1-dmso-9-017){ref-type="table"}). OAD treated patients had more often a diagnosis of hypertension, dyslipidemia, obesity, and depression than insulin users ([Table 1](#t1-dmso-9-017){ref-type="table"}). There were no substantial differences in prevalence of macrovascular complications between the two groups, except for peripheral vascular disease, which was more often found among insulin users. Finally, baseline HbA~lc~ was higher among patients who started insulin, whereas BMI was slightly increased among OAD users ([Table 1](#t1-dmso-9-017){ref-type="table"}).

Compared to patients with newly prescribed insulin therapy, there was a lower odds of fractures in patients with OAD, although not statistically significant. In a final model (stepwise selection), the corresponding odds ratio for having ≥1 fracture was 0.87 (95% confidence interval: 0.72; 1.06) for OAD versus insulin use ([Table 2](#t2-dmso-9-017){ref-type="table"}). An increased odds of having any fractures was found for higher age, heart failure, and peripheral arterial disease in the multivariable model. Diabetologist care was significantly related to a lower odds of fractures ([Table 2](#t2-dmso-9-017){ref-type="table"}). Finally, men showed a lower chance of having fractures compared to women with type 2 diabetes.

Fracture risk in BOT, CT, and SIT
---------------------------------

In the observation period, there were 15,852 prevalent insulin users with BOT, 10,995 with CT, and 14,542 with SIT, respectively ([Table 3](#t3-dmso-9-017){ref-type="table"}). The CT group was older, comprised more females, and had a shorter diabetes duration in the practices than the other two cohorts (BOT, SIT). Forty-two percent of SIT users were in diabetologist care, which was higher than in the other groups. Hypertension was frequently documented in all insulin regimens, whereas prevalence of hyperlipidemia and obesity was the highest in the BOT patients. No difference was observed for prevalence of myocardial infarction between the three groups. Frequency of microvascular complications was also comparable except for nephropathy, which was more often found in BOT users who also had the highest proportion of concomitant hypertension. Average HbA~lc~ and BMI were similar in all insulin groups as well as a low prevalence of patients with documented hypoglycemia. As expected, comedication with oral antidiabetic agents and GLP-1-based drugs was the highest in the BOT cohort.

The mean follow-up times were 1.5 years in BOT, 1.8 years in CT, and 0.9 years in SIT users, respectively. There were 601 (3.8%) patients with fractures among BOT users (CT: n=633, 5.8%; SIT: n=508, 3.5%) (*P*\<0.0001). There was an indication that CT users had a higher chance of any fractures compared to the BOT regimen which, however, was not statistically significant in multivariable analysis ([Table 4](#t4-dmso-9-017){ref-type="table"}). There was no increased OR for SIT users (reference: BOT). Age was related to an increased odds, whereas male sex and diabetologist care were both related to a lower chance of fractures. Finally, comedication with sulfonylureas was related to a higher odds of fractures.

Fracture risk among basal insulin users
---------------------------------------

There were 5,408 type 2 diabetes patients using insulin glargine in the observation period (detemir: n=1,569; NPH insulin: n=6,762). The mean follow-up in insulin glargine users was 1.7 years (detemir: 1.7 years; NPH: 2.0 years). There were 708 (4.1%) patients on glargine treatment who experienced at least one fracture during the study period (detemir: n=184, 3.6%; NPH: n=698, 3.8%).

Insulin glargine-treated patients were slightly older than detemir and NPH users ([Table 5](#t5-dmso-9-017){ref-type="table"}). Diabetes duration recorded in the practices was somewhat longer in glargine and detemir users than in the NPH group. Patients with NPH basal insulin were more frequently treated in diabetologist care than the other two groups ([Table 5](#t5-dmso-9-017){ref-type="table"}). The prevalence of macrovascular complications and related risk factors (hypertension, hyperlipidemia) was comparable for the three treatment regimens. Microvascular complications (retinopathy, neuropathy) were more frequently recorded in the detemir and NPH cohorts than in glargine users ([Table 5](#t5-dmso-9-017){ref-type="table"}). Finally, heart failure and depression were more often found in the glargine group.

Baseline BMI and prevalence of diagnosed obesity were high in all three groups. Average HbA~lc~ levels were somewhat higher in glargine and detemir users, whereas prevalence of documented hypoglycemia was low in all three cohorts ([Table 5](#t5-dmso-9-017){ref-type="table"}). All basal insulin regimens were frequently treated with additional short acting insulins (62%--81%). Sulfonylureas were more often prescribed in glargine users and DPP-4 inhibitors were less often used in the NPH group compared to the other two cohorts ([Table 5](#t5-dmso-9-017){ref-type="table"}).

Overall, there was no difference in fracture risk between various basal insulin users (glargine, detemir, NPH). There was an indication that treatment duration with basal insulin had an impact on fracture risk (data not shown). Therefore, only patients with a minimum basal insulin treatment duration of 2 years were included ([Table 6](#t6-dmso-9-017){ref-type="table"}). In these analyses, insulin glargine was related to a lower odds of having any fractures compared to NPH use ([Table 6](#t6-dmso-9-017){ref-type="table"}). No difference was observed between the detemir and NPH cohorts. Furthermore, male sex and diabetologist care were significantly related to a lower odds of fractures, whereas heart failure was associated with a higher chance of experiencing ≥1 fracture ([Table 6](#t6-dmso-9-017){ref-type="table"}).

Discussion
==========

The results of this study indicate that initiation of insulin therapy in patients with type 2 diabetes is associated with an increased risk of fractures overall. Type 2 diabetes patients with oral antidiabetic agents had a 13% lower chance of having any fracture during an average of 2.5 years of follow-up compared to incident insulin users, although not statistically significant due to relatively few outcomes and short observation times.

The underlying mechanisms for this difference in fracture risk are not clear. A possible cause of the increased risk of fracture in insulin-treated type 2 diabetes is hypoglycemia, which may increase the risk of falling. Furthermore, diabetes-related comorbidity, such as diabetic retinopathy (disturbed vision) and peripheral neuropathy (problems with balance as well as neurological and musculoskeletal disabilities), may contribute to frequent falls to increase the risk of fractures. Although a higher bone mineral density has been found in type 2 diabetes compared to control subjects, a deterioration in bone microarchitecture and an inefficient distribution of bone mass in combination with insufficient repair and adaption mechanisms all lead to skeletal complications of diabetes.[@b18-dmso-9-017] Factors circulating in the blood of type 2 diabetes patients may affect osteoblast function, for example, an increase of transforming growth factor-β may be a pathogenic mechanism underlying poor bone formation.[@b19-dmso-9-017] Thus, a combination of poor bone quality and more frequent falls due to hypoglycemia and increased diabetes-related comorbidity may increase the risk of fracture, in particular among insulin-treated type 2 diabetes patients.[@b20-dmso-9-017]

There was also an indication that conventional insulin treatment, which is carried out with premixed short and long-acting insulin, is related to an increased fracture risk compared to type 2 diabetes patients with BOT. Furthermore, a lower risk of any fracture was observed among insulin glargine users compared to NPH basal insulin. However, this lower chance was only observed after a longer treatment duration of at least 2 years.

It is conceivable that the lower risk of hypoglycemia in BOT[@b21-dmso-9-017]--[@b23-dmso-9-017] and glargine treatment[@b24-dmso-9-017],[@b25-dmso-9-017] mainly contributed to the lower chance of experiencing any fractures. Unfortunately, the prevalence of documented hypoglycemia was low in the Disease Analyzer database, which hampered the investigation of the impact of hypoglycemia on fracture risk in the present study. Hypoglycemia-induced falls are common in type 2 diabetes patients.[@b26-dmso-9-017] The etiology of falls in type 2 diabetes is multifactorial, including microvascular complications and other age-related comorbidities, with hypoglycemia as a major underlying causal factor.[@b26-dmso-9-017] In particular, insulin-treated patients are more likely to experience falls during a hypoglycemic episode.[@b27-dmso-9-017]

In the present study, sulfonylurea prescriptions were also identified as an independent risk factor for fractures in one of the regression analyses (insulin vs OAD). Sulfonlyurea treatment is associated with an increased risk of hypoglycemia.[@b28-dmso-9-017] However, the few studies on the link between sulfonylurea treatment and fall-related fractures yielded conflicting results and suffered from several methodological limitations.[@b28-dmso-9-017] Thus, future studies are needed to investigate the relationship between sulfonylureas and fracture risk in type 2 diabetes.

In line with the present study, women with type 2 diabetes were more likely to develop fractures as a result of falls when compared with men in a previous investigation.[@b29-dmso-9-017] In the Third National Health and Nutrition Examination Survey in the US, diabetes was also more frequently associated with slower walking speed, inferior lower-extremity function, decreased balance, and an increased risk of falling in women than in men.[@b30-dmso-9-017]

A known risk factor associated with the development of fractures is older age, which was also observed in the present study.[@b31-dmso-9-017] Furthermore, heart failure was previously identified as a risk factor for fractures in the older population, which could be confirmed in the present study in older patients with type 2 diabetes.[@b32-dmso-9-017] The relationship between peripheral arterial disease found in the present and previous studies may be due to lower bone mineral density.[@b33-dmso-9-017] Finally, as a novel finding, diabetologist care was independently related to a lower chance of fractures in insulin-treated type 2 diabetes in the current investigation, which needs to be confirmed in further studies. Most likely, multiple factors, including a more intensive diabetes control and reduction of hypoglycemia contribute to the lower fracture risk.

Several limitations of the present study should be mentioned. First, no valid information on diabetes type and prescribed daily doses of medications were available in the database. Furthermore, no valid information on diabetes duration was provided. Also assessment of fractures and comorbidity relied on ICD codes by primary care physicians exclusively. It is noteworthy that the significantly reduced fracture risk among glargine compared to NPH users was found in a post hoc analysis taking into account a minimum insulin treatment duration of 2 years. This finding most likely reflects that insulin initiation and titration is a challenge in a number of type 2 diabetes patients during the first 1--2 years. Finally, measurements of HbA~lc~ and BMI values were not standardized. The strength of the study is the large nationwide database and unbiased assessment of prescriptions.

In conclusion, initiation of insulin therapy in primary care patients with type 2 diabetes seems to be associated with an increased risk of fractures overall. The observed lower fracture risk in patients with BOT and long-term glargine therapy is most likely due to a lower risk of hypoglycemia-related falls, which needs to be investigated in future studies.
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###### 

Baseline characteristics of primary care patients with incident insulin therapy or oral antidiabetic drug (OAD) treatment (Disease Analyzer database, IMS Health, Frankfurt, Germany)

  Variables                              OAD                                                      Insulin
  -------------------------------------- -------------------------------------------------------- --------------------------------------------------------
  N                                      81,710                                                   24,250
  Age (years)                            63.1 (12.4)[\*](#tfn2-dmso-9-017){ref-type="table-fn"}   66.4 (13.9)[\*](#tfn2-dmso-9-017){ref-type="table-fn"}
  Male sex (%)                           54.3[\*](#tfn2-dmso-9-017){ref-type="table-fn"}          51.9[\*](#tfn2-dmso-9-017){ref-type="table-fn"}
  Diabetes duration (years)              0.8 (1.8)[\*](#tfn2-dmso-9-017){ref-type="table-fn"}     0.7 (1.8)[\*](#tfn2-dmso-9-017){ref-type="table-fn"}
  Private health insurance (%)           7.0[\*](#tfn2-dmso-9-017){ref-type="table-fn"}           4.2[\*](#tfn2-dmso-9-017){ref-type="table-fn"}
  Diabetologist care (%)                 15.4[\*](#tfn2-dmso-9-017){ref-type="table-fn"}          43.1[\*](#tfn2-dmso-9-017){ref-type="table-fn"}
  **Baseline diagnoses**                                                                          
  Hypertension (%)                       62.4[\*](#tfn2-dmso-9-017){ref-type="table-fn"}          46.9[\*](#tfn2-dmso-9-017){ref-type="table-fn"}
  Hyperlipidemia (%)                     34.6[\*](#tfn2-dmso-9-017){ref-type="table-fn"}          21.0[\*](#tfn2-dmso-9-017){ref-type="table-fn"}
  Obesity (%)                            19.0[\*](#tfn2-dmso-9-017){ref-type="table-fn"}          11.9[\*](#tfn2-dmso-9-017){ref-type="table-fn"}
  Myocardial infarction (%)              4.2[\*](#tfn2-dmso-9-017){ref-type="table-fn"}           5.1[\*](#tfn2-dmso-9-017){ref-type="table-fn"}
  Coronary heart disease (%)             16.1[\*](#tfn2-dmso-9-017){ref-type="table-fn"}          17.5[\*](#tfn2-dmso-9-017){ref-type="table-fn"}
  Peripheral vascular disease (%)        4.9[\*](#tfn2-dmso-9-017){ref-type="table-fn"}           10.7[\*](#tfn2-dmso-9-017){ref-type="table-fn"}
  Peripheral neuropathy (%)              4.7[\*](#tfn2-dmso-9-017){ref-type="table-fn"}           14.4[\*](#tfn2-dmso-9-017){ref-type="table-fn"}
  Retinopathy (%)                        1.3[\*](#tfn2-dmso-9-017){ref-type="table-fn"}           5.7[\*](#tfn2-dmso-9-017){ref-type="table-fn"}
  Nephropathy (%)                        4.9[\*](#tfn2-dmso-9-017){ref-type="table-fn"}           13.8[\*](#tfn2-dmso-9-017){ref-type="table-fn"}
  Heart failure (%)                      5.9[\*](#tfn2-dmso-9-017){ref-type="table-fn"}           8.0[\*](#tfn2-dmso-9-017){ref-type="table-fn"}
  Depression (%)                         9.4[\*](#tfn2-dmso-9-017){ref-type="table-fn"}           4.7[\*](#tfn2-dmso-9-017){ref-type="table-fn"}
  Charlson Comorbidity Score             1.3 (0.8)[\*](#tfn2-dmso-9-017){ref-type="table-fn"}     1.7 (1.1)[\*](#tfn2-dmso-9-017){ref-type="table-fn"}
  HbA~lc~% (baseline)                    7.5 (1.6)[\*](#tfn2-dmso-9-017){ref-type="table-fn"}     8.2 (2.0)[\*](#tfn2-dmso-9-017){ref-type="table-fn"}
  Body mass index (kg/m^2^) (baseline)   31.7 (5.6)[\*](#tfn2-dmso-9-017){ref-type="table-fn"}    30.1 (5.9)[\*](#tfn2-dmso-9-017){ref-type="table-fn"}

**Notes:** Data are mean (standard deviation) or proportions (%).

*P*\<0.05 OAD versus insulin.

###### 

Multivariate logistic regression model for developing any fractures in type 2 diabetes patients in primary care practices

  Variables                              Odds ratio (95% CI)   *P*-value
  -------------------------------------- --------------------- -----------
  OAD versus insulin treatment           0.87 (0.72--1.06)     0.1744
  Age (year)                             1.04 (1.03--1.05)     \<0.0001
  Male sex (yes/no)                      0.59 (0.50--0.69)     \<0.0001
  Diabetologist care (yes/no)            0.32 (0.24--0.43)     \<0.0001
  Heart failure (yes/no)                 1.31 (1.02--1.67)     0.0330
  Peripheral arterial disease (yes/no)   1.48 (1.11--1.95)     0.0069

**Note:** Final model after stepwise selection of all variables.

**Abbreviations:** CI, confidence interval; OAD, oral antidiabetic drug (including GLP-1-based therapies).

###### 

Baseline characteristics of insulin-treated type 2 diabetes primary care patients with BOT, CT, or SIT (Disease Analyzer database, IMS Health, Frankfurt, Germany)

  Variables                              BOT           CT            SIT           *P*-value
  -------------------------------------- ------------- ------------- ------------- -----------
  N                                      15,852        10,995        14,542        --
  Age (years)                            64.1 (15.5)   71.8 (11.4)   62.3 (13.5)   \<0.0001
  Male sex (%)                           54.4          44.2          54.5          \<0.0001
  Diabetes duration (years)              1.6 (2.5)     0.8 (1.9)     1.0 (2.1)     \<0.0001
  Private health insurance (%)           5.8           3.6           4.2           \<0.0001
  Diabetologist care (%)                 37.2          28.9          42.1          \<0.0001
  **Baseline diagnoses**                                                           
  Hypertension (%)                       56.8          51.5          47.1          \<0.0001
  Hyperlipidemia (%)                     32.0          21.7          23.2          \<0.0001
  Obesity (%)                            20.0          11.6          16.6          \<0.0001
  Myocardial infarction (%)              5.0           5.1           4.6           0.1513
  Coronary heart disease (%)             17.7          20.4          14.8          \<0.0001
  Peripheral vascular disease (%)        9.6           10.0          9.0           0.0318
  Peripheral neuropathy (%)              14.3          11.9          13.4          \<0.0001
  Retinopathy (%)                        4.6           3.8           5.2           \<0.0001
  Nephropathy (%)                        19.8          10.9          9.8           0.0046
  Heart failure (%)                      8.0           11.4          5.7           \<0.0001
  Depression (%)                         7.7           6.1           5.4           \<0.0001
  Charlson Comorbidity Score             1.6 (1.1)     1.6 (1.1)     1.6 (1.1)     0.0042
  HbA~lc~ (%) (baseline)                 8.6 (1.9)     8.4 (1.9)     8.4 (2.1)     \<0.0001
  Body mass index (kg/m^2^) (baseline)   31.4 (5.7)    30.4 (5.4)    31.4 (6.0)    \<0.0001
  Documented hypoglycemia (%)            1.1           0.9           1.4           0.0003
  **Comedication (%)**                                                             
  Metformin                              68.4          22.3          21.4          \<0.0001
  Sulfonylurea                           19.7          8.1           3.0           \<0.0001
  DPP-4 inhibitors                       18.0          3.5           3.3           \<0.0001
  GLP-1 receptor agonists                3.9           0.3           0.8           \<0.0001

**Notes:** Data are mean (standard deviation) or proportions (%). *P*-value: Kruskal--Wallis tests.

**Abbreviations:** BOT, basal-supported oral therapy; CT, conventional insulin therapy; SIT, supplementary insulin therapy.

###### 

Multivariate logistic regression model for developing any fractures in type 2 diabetes patients in primary care practices

  Variables                     Odds ratio (95% CI)   *P*-value
  ----------------------------- --------------------- -----------
  CT versus BOT                 1.59 (0.89--2.84)     0.1194
  SIT versus BOT                1.20 (0.63--2.27)     0.5834
  Age (year)                    1.03 (1.00--1.05)     0.0190
  Male sex (yes/no)             0.48 (0.29--0.79)     0.0038
  Diabetologist care (yes/no)   0.53 (0.28--0.99)     0.0463
  Sulfonylurea (yes/no)         1.86 (1.06--3.29)     0.0320

**Note:** Final model after stepwise selection of all variables.

**Abbreviations:** BOT, basal-supported oral therapy; CI, confidence interval; CT, conventional insulin therapy; SIT, supplementary insulin therapy.

###### 

Baseline characteristics of insulin-treated type 2 diabetes primary care patients with insulin glargine, detemir, and NPH insulin

  Variables                              Glargine      Detemir       NPH           *P* value
  -------------------------------------- ------------- ------------- ------------- -----------
  N                                      5,408         1,569         6,762         
  Age (years)                            65.5 (12.1)   62.4 (12.0)   63.9 (11.6)   \<0.0001
  Male sex (%)                           54.8          54.5          53.6          0.3934
  Diabetes duration (years)              2.0 (2.7)     1.9 (2.7)     1.5 (2.3)     \<0.0001
  Private health insurance (%)           5.7           6.7           3.5           \<0.0001
  Diabetologist care (%)                 34.9          44.5          50.6          \<0.0001
  **Baseline diagnoses**                                                           
  Hypertension (%)                       64.4          60.0          60.6          \<0.0001
  Hyperlipidemia (%)                     39.1          38.1          35.6          0.0003
  Obesity (%)                            19.5          22.2          19.7          0.0475
  Myocardial infarction (%)              7.3           6.0           6.4           0.0625
  Coronary heart disease (%)             23.2          20.5          20.3          0.0002
  Peripheral vascular disease (%)        12.2          13.8          13.5          0.0644
  Peripheral neuropathy (%)              16.8          20.9          19.4          \<0.0001
  Retinopathy (%)                        6.8           9.1           8.0           0.0030
  Nephropathy (%)                        14.3          13.1          11.5          \<0.0001
  Heart failure (%)                      10.2          7.1           8.6           \<0.0001
  Depression (%)                         9.7           8.7           7.5           \<0.0001
  Charlson Comorbidity Score             1.8 (1.2)     1.8 (1.1)     1.8 (1.1)     0.0984
  HbA~lc~% (baseline)                    8.5 (1.8)     8.6 (1.9)     8.2 (1.7)     \<0.0001
  Body mass index (kg/m^2^) (baseline)   30.8 (5.7)    32.0 (6.0)    31.8 (5.9)    \<0.0001
  Documented hypoglycemia (%)            1.3           2.6           1.5           0.0025
  **Comedication (%)**                                                             
  Short acting insulins                  61.2          78.9          81.1          \<0.0001
  Metformin                              44.4          49.1          48.3          \<0.0001
  Sulfonylurea                           19.5          12.7          12.8          \<0.0001
  DPP-4 inhibitors                       21.2          22.5          12.1          \<0.0001
  GLP-1 receptor agonists                3.6           8.6           2.7           \<0.0001

**Notes:** Data are mean (standard deviation) or proportions (%). *P*-value: Kruskal--Wallis tests.

###### 

Multivariate logistic regression model for developing any fractures in type 2 diabetes patients in primary care practices

  Variables                                                                       Odds ratio (95% CI)   *P*-value
  ------------------------------------------------------------------------------- --------------------- -----------
  Glargine versus NPH basal insulin[\*](#tfn11-dmso-9-017){ref-type="table-fn"}   0.69 (0.50--0.96)     0.0264
  Detemir versus NPH basal insulin[\*](#tfn11-dmso-9-017){ref-type="table-fn"}    0.94 (0.59--1.49)     0.7842
  Male sex (yes/no)                                                               0.62 (0.46--0.84)     0.0021
  Diabetologist care (yes/no)                                                     0.26 (0.16--0.43)     \<0.0001
  Heart failure (yes/no)                                                          1.55 (1.06--2.28)     0.0237

**Notes:** Final model after stepwise selection of all variables.

Minimum basal insulin treatment duration: 2 years.

**Abbreviation:** CI, confidence interval.
